| Source: |
| Type: |
| Toxicity |
| 1341- | 3BP, | The HK2 Dependent “Warburg Effect” and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate |
| - | Review, | NA, | NA |
| 5278- | 3BP, | The effect of 3-bromopyruvate on human colorectal cancer cells is dependent on glucose concentration but not hexokinase II expression |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | Caco-2 | - | in-vitro, | CRC, | SW48 |
| 5274- | 3BP, | ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1 |
| - | in-vitro, | PC, | NA |
| 5259- | 3BP, | Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP |
| - | in-vivo, | HCC, | NA |
| 5260- | 3BP, | Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer |
| - | in-vivo, | PC, | NA |
| 5269- | 3BP, | The anti-metabolite KAT/3BP has in vitro and in vivo anti-tumor activity in lymphoma models. |
| - | in-vitro, | HCC, | NA |
| 5295- | 5-HTP, | Safety of 5-hydroxy-L-tryptophan |
| - | in-vivo, | Nor, | NA |
| 5466- | AF, | Auranofin Inhibition of Thioredoxin Reductase in a Preclinical Model of Small Cell Lung Cancer |
| - | in-vivo, | Lung, | NA |
| 5458- | AF, | Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer |
| - | in-vitro, | NSCLC, | NA |
| 5468- | AF, | The gold complex auranofin: new perspectives for cancer therapy |
| - | Review, | Var, | NA |
| 5443- | AG, | Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers |
| - | Human, | Nor, | NA |
| 5436- | AG, | Therapeutic Effect of Astragalus Polysaccharides on Hepatocellular Carcinoma H22-Bearing Mice |
| - | in-vivo, | HCC, | NA |
| 4360- | AgNPs, | Silver Nanoparticles as Real Topical Bullets for Wound Healing |
| - | Study, | Nor, | NA |
| 4359- | AgNPs, | Antimicrobial Silver Nanoparticles for Wound Healing Application: Progress and Future Trends |
| - | NA, | Wounds, | NA |
| - | vitro+vivo, | Nor, | NA |
| 4447- | AgNPs, | Anti-inflammatory action of silver nanoparticles in vivo: systematic review and meta-analysis |
| - | Review, | Nor, | NA |
| 4365- | AgNPs, | Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview |
| - | Review, | Var, | NA |
| 4561- | AgNPs, | VitC, | Cellular Effects Nanosilver on Cancer and Non-cancer Cells: Potential Environmental and Human Health Impacts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | HEK293 |
| 4556- | AgNPs, | Biofilm Impeding AgNPs Target Skin Carcinoma by Inducing Mitochondrial Membrane Depolarization Mediated through ROS Production |
| - | in-vitro, | Melanoma, | A431 |
| 4600- | AgNPs, | Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model |
| - | in-vivo, | Nor, | NA |
| 4581- | AgNPs, | Antimicrobial, anticoagulant and antiplatelet activities of green synthesized silver nanoparticles using Selaginella (Sanjeevini) plant extract |
| 4573- | AgNPs, | Bioactive silver nanoparticles derived from Carica papaya floral extract and its dual-functioning biomedical application |
| - | in-vitro, | Var, | MCF-7 | - | NA, | NA, | HEK293 |
| 375- | AgNPs, | ALA, | Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer |
| - | in-vitro, | PC, | Bxpc-3 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vivo, | NA, | NA |
| 305- | AgNPs, | Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer |
| - | Case Report, | HNSCC, | NA |
| 359- | AgNPs, | Anti-cancer & anti-metastasis properties of bioorganic-capped silver nanoparticles fabricated from Juniperus chinensis extract against lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 |
| 346- | AgNPs, | RSQ, | Investigating Silver Nanoparticles and Resiquimod as a Local Melanoma Treatment |
| - | in-vivo, | Melanoma, | SK-MEL-28 | - | in-vivo, | Melanoma, | WM35 |
| 2538- | AgNPs, | SDT, | Z, | Dual-functional silver nanoparticle-enhanced ZnO nanorods for improved reactive oxygen species generation and cancer treatment |
| - | Study, | Var, | NA | - | vitro+vivo, | NA, | NA |
| 5353- | AL, | Aged Garlic Extract May Be Safe for Patients on Warfarin Therapy |
| - | Human, | Nor, | NA |
| 1069- | AL, | Allicin promotes autophagy and ferroptosis in esophageal squamous cell carcinoma by activating AMPK/mTOR signaling |
| - | vitro+vivo, | ESCC, | TE1 | - | vitro+vivo, | ESCC, | KYSE-510 | - | in-vitro, | Nor, | Het-1A |
| 245- | AL, | Allicin: a promising modulator of apoptosis and survival signaling in cancer |
| - | Review, | Var, | NA |
| 285- | ALA, | HCA, | Tolerance of oral lipoid acid and hydroxycitrate combination in cancer patients: first approach of the cancer metabolism research group |
| - | Human, | Var, | NA |
| 1235- | ALA, | Cisplatin, | α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway |
| - | in-vitro, | Nor, | HEI-OC1 | - | ex-vivo, | NA, | NA |
| 1078- | And, | Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HUVECs | - | in-vivo, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MDA-MB-361 |
| 1999- | Api, | doxoR, | Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation |
| - | in-vitro, | Nor, | NRK52E | - | in-vitro, | Nor, | MPC5 | - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 1548- | Api, | A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms |
| - | Review, | Colon, | NA |
| 1147- | ART/DHA, | Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1 |
| - | vitro+vivo, | Ovarian, | HO-8910 | - | vitro+vivo, | Nor, | HUVECs |
| 2570- | ART/DHA, | Discovery, mechanisms of action and combination therapy of artemisinin |
| - | Review, | Nor, | NA |
| 2582- | ART/DHA, | 5-ALA, | Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity |
| - | in-vivo, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT116 |
| 5414- | ASA, | Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against |
| - | Review, | Var, | NA |
| 3172- | Ash, | Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | HL7702 |
| 3160- | Ash, | Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal |
| - | Review, | Var, | NA |
| 1368- | Ash, | Cisplatin, | Withania somnifera Root Extract Enhances Chemotherapy through ‘Priming’ |
| - | in-vitro, | Colon, | HT-29 | - | in-vitro, | BC, | MDA-MB-231 |
| 1365- | Ash, | Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells |
| - | in-vitro, | Oral, | Ca9-22 | - | in-vitro, | Oral, | CAL27 |
| 1173- | Ash, | Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling |
| - | in-vitro, | EC, | K1 | - | in-vitro, | Nor, | THESCs |
| 2001- | Ash, | Withania somnifera: from prevention to treatment of cancer |
| - | Review, | Var, | NA |
| 5391- | AsP, | Research Progress of Ascorbyl Palmitate in Drug Delivery and Cancer Therapy |
| - | Review, | Var, | NA |
| 5372- | ATO, | Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia |
| - | Trial, | APL, | NA |
| 5374- | ATO, | A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia |
| - | Trial, | APL, | NA |
| 5448- | ATV, | Beyond cardiovascular health: The pharmacotherapeutic potential of statins in oncology |
| - | Review, | Var, | NA |
| 5449- | ATV, | Pleiotropic effects of statins: A focus on cancer |
| - | NA, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1025 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid